UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011401
Receipt number R000013303
Scientific Title The anti-inflammatory and organ protective effect of Teprenone
Date of disclosure of the study information 2013/08/15
Last modified on 2018/09/12 14:32:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The anti-inflammatory and organ protective effect of Teprenone

Acronym

The anti-inflammatory and organ protective effect of Teprenone

Scientific Title

The anti-inflammatory and organ protective effect of Teprenone

Scientific Title:Acronym

The anti-inflammatory and organ protective effect of Teprenone

Region

Japan


Condition

Condition

perioperative patient(malignant tumor, rheumatism, maitenance dyalisis, administration of steroids are excluded)

Classification by specialty

Anesthesiology Operative medicine Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Renal or hepatic disfunction can occur after surgical operation caused by operative invasion, administration of perioperative drugs, and changing of hemodynamics. Teprenon has been used clinicalliy as anti-ulcer drugs for 20 years or more. Recently, Teprenon showed an induction of heat shock protein 70, and excerted cytoprotective and anti-inflammatory effects on various cells and tissues like liver, kidney, lung, heart, and brain. But there are few clinical studies on human. Our study can reveal the perioperative protective effect on multiple organ of Teperenon in human.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum CRP, WBC, AST, ALT, BUN, Crea, IL-6, IL-8 and TNF-alpha of blood sample in pre operation, post operation, 1,3 and 6th day after operation.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Administration of Teprenone

Interventions/Control_2

Control(No medication)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

peri operative patient

Key exclusion criteria

maintenance hemodyalisis, malignant tumor, administration of steroids, rheumatism

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuko Nakano

Organization

Fukushima Medical University

Division name

Department of Anesthesiolosy

Zip code


Address

1 Hikarigaoka, Fukushima-City, Fukushima-Pref, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Fukushima Medical University

Division name

Department of Anesthesiolosy

Zip code


Address

Hikarigaoka, Fukushima-City, Fukushima-Pref, Japan

TEL


Homepage URL


Email



Sponsor or person

Institute

Fukushima Medical University

Institute

Department

Personal name



Funding Source

Organization

Fukushima Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 08 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 08 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 08 Month 07 Day

Last modified on

2018 Year 09 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013303


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name